Title: 2025-2026 Regular Session SR 122 PN 0905 Bill Text (HTM)
Official Title: 
Number of Sections: 1
Source: versions - Printer's No. PN0905
Media Type: text/html

================================================================================

Section 1:
2025-2026 Regular Session SR 122 PN 0905 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 905 THE GENERAL ASSEMBLY OF PENNSYLVANIASENATE RESOLUTION No.122 Session of 2025 INTRODUCED BY PENNYCUICK, ROBINSON, DUSH, MASTRIANO, YAW, ROTHMAN AND BARTOLOTTA, JUNE 6, 2025 REFERRED TO VETERANS AFFAIRS AND EMERGENCY PREPAREDNESS, JUNE 6, 2025 A RESOLUTIONUrging the Congress of the United States to expand post-traumatic stress disorder treatment for veterans and service members by authorizing stellate ganglion block therapy through passage of H.R. 1947, the Treatment and Relief through Emerging and Accessible Therapy for PTSD Act.WHEREAS, A stellate ganglion block (SGB) procedure injects an anesthetic agent on the stellate ganglion, a collection of nerves in the neck that controls the activation of the "fight or flight" survival reflex; andWHEREAS, SGB is proven to alleviate common post-traumatic stress disorder (PTSD) symptoms such as hyperarousal, exaggerated startle responses and anxiety; andWHEREAS, The procedure has been performed since the 1920s and is considered low risk; andWHEREAS, SGB was first recognized as a treatment for PTSD in 2008; andWHEREAS, The United States Department of Veterans Affairs (VA) estimates that 29% of Operation Enduring Freedom and Operation Iraqi Freedom veterans have received a diagnosis of 12345678910111213141516171819 PTSD; andWHEREAS, Older veterans are also impacted, with the VA estimating that 21% of Persian Gulf War veterans and 10% of Vietnam veterans receive a PTSD diagnosis; andWHEREAS, Unfortunately, only 40% of veterans find relief from PTSD with current treatments; andWHEREAS, If left untreated, PTSD symptoms have a positive correlation with suicide risk; andWHEREAS, The lack of effective PTSD treatments directly contributes to the 20 veteran suicides the United States experiences each day; andWHEREAS, H.R. 1947 directs the United States Secretary of Veterans Affairs and the United States Secretary of Defense to furnish SGB therapy to veterans and members of the armed forces of the United States with PTSD; andWHEREAS, H.R. 1947 is supported by the Pennsylvania National Guard Associations, the American Legion and behavioral health clinicians; therefore be itRESOLVED, That the Senate urge the Congress of the United States to expand post-traumatic stress disorder treatment for veterans and service members by authorizing stellate ganglion block therapy through passage of H.R. 1947, the Treatment and Relief through Emerging and Accessible Therapy for PTSD Act; and be it furtherRESOLVED, That copies of this resolution be transmitted to the President of the United States, the presiding officers of each house of Congress and to each member of Congress from Pennsylvania.20250SR0122PN0905 - 2 - 12345678910111213141516171819202122232425262728


================================================================================

Raw Text:
2025-2026 Regular Session SR 122 PN 0905 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 905 THE GENERAL ASSEMBLY OF PENNSYLVANIASENATE RESOLUTION No.122 Session of 2025 INTRODUCED BY PENNYCUICK, ROBINSON, DUSH, MASTRIANO, YAW, ROTHMAN AND BARTOLOTTA, JUNE 6, 2025 REFERRED TO VETERANS AFFAIRS AND EMERGENCY PREPAREDNESS, JUNE 6, 2025 A RESOLUTIONUrging the Congress of the United States to expand post-traumatic stress disorder treatment for veterans and service members by authorizing stellate ganglion block therapy through passage of H.R. 1947, the Treatment and Relief through Emerging and Accessible Therapy for PTSD Act.WHEREAS, A stellate ganglion block (SGB) procedure injects an anesthetic agent on the stellate ganglion, a collection of nerves in the neck that controls the activation of the "fight or flight" survival reflex; andWHEREAS, SGB is proven to alleviate common post-traumatic stress disorder (PTSD) symptoms such as hyperarousal, exaggerated startle responses and anxiety; andWHEREAS, The procedure has been performed since the 1920s and is considered low risk; andWHEREAS, SGB was first recognized as a treatment for PTSD in 2008; andWHEREAS, The United States Department of Veterans Affairs (VA) estimates that 29% of Operation Enduring Freedom and Operation Iraqi Freedom veterans have received a diagnosis of 12345678910111213141516171819 PTSD; andWHEREAS, Older veterans are also impacted, with the VA estimating that 21% of Persian Gulf War veterans and 10% of Vietnam veterans receive a PTSD diagnosis; andWHEREAS, Unfortunately, only 40% of veterans find relief from PTSD with current treatments; andWHEREAS, If left untreated, PTSD symptoms have a positive correlation with suicide risk; andWHEREAS, The lack of effective PTSD treatments directly contributes to the 20 veteran suicides the United States experiences each day; andWHEREAS, H.R. 1947 directs the United States Secretary of Veterans Affairs and the United States Secretary of Defense to furnish SGB therapy to veterans and members of the armed forces of the United States with PTSD; andWHEREAS, H.R. 1947 is supported by the Pennsylvania National Guard Associations, the American Legion and behavioral health clinicians; therefore be itRESOLVED, That the Senate urge the Congress of the United States to expand post-traumatic stress disorder treatment for veterans and service members by authorizing stellate ganglion block therapy through passage of H.R. 1947, the Treatment and Relief through Emerging and Accessible Therapy for PTSD Act; and be it furtherRESOLVED, That copies of this resolution be transmitted to the President of the United States, the presiding officers of each house of Congress and to each member of Congress from Pennsylvania.20250SR0122PN0905 - 2 - 12345678910111213141516171819202122232425262728